Spyre Therapeutics Inc. (SYRE) announced the pricing of its underwritten public offering of about 7.28 million shares of its common stock at a price to the public of $27.50 per share.
The company expects aggregate gross proceeds from the offering to be $200.0 million, before deducting underwriting discounts and commissions and other offering expenses.
In addition, the company has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 1.09 million shares of the Company's common stock at the public offering price, less the underwriting discount.
The offering is expected to close on or about November 20, 2024.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.